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Abstract
Background Due to population aging, an increasing num-
ber of elderly patients with diabetes use insulin. It is
therefore important to investigate the characteristics of new
insulins in this population. Faster-acting insulin aspart
(faster aspart) is insulin aspart (IAsp) in a new formulation
with faster absorption. This study investigated the phar-
macological properties of faster aspart in elderly subjects
with type 1 diabetes mellitus (T1DM).
Methods In a randomised, double-blind, two-period cross-
over trial, 30 elderly (C65 years) and 37 younger adults
(18–35 years) with T1DM received single subcutaneous
faster aspart or IAsp dosing (0.2 U/kg) and underwent an
euglycaemic clamp (target 5.5 mmol/L) for up to 12 h.
Results The pharmacokinetic and pharmacodynamic time
profiles were left-shifted for faster aspart versus IAsp. In
each age group, onset of appearance occurred approxi-
mately twice as fast (*3 min earlier) and early exposure
(area under the concentration–time curve [AUC] for serum
IAsp from time zero to 30 min [AUCIAsp,0-30 min]) was
greater (by 86% in elderly and 67% in younger adults) for
faster aspart than for IAsp. Likewise, onset of action
occurred 10 min faster in the elderly and 9 min faster in
younger adults, and early glucose-lowering effect (AUC
for the glucose infusion rate [GIR] from time zero to
30 min [AUCGIR,0-30 min]) was greater (by 109%) for faster
aspart than for IAsp in both age groups. Total exposure
(AUCIAsp,0-t) and the maximum concentration (Cmax) for
faster aspart were greater (by 30 and 28%, respectively) in
elderly than in younger adults. No age group differences
were seen for the total (AUCGIR,0-t) or maximum (GIRmax)
glucose-lowering effect.
Conclusion This study demonstrated that the ultra-fast
pharmacological properties of faster aspart are similar in
elderly subjects and younger adults with T1DM.
ClinicalTrials.gov Identifier: NCT02003677.
Key Points
In elderly subjects with type 1 diabetes mellitus,
onset of appearance was twice as fast and early
insulin exposure and early glucose-lowering effect
were up to twofold greater for faster-acting insulin
aspart (faster aspart) than for insulin aspart.
While the total exposure and maximum
concentration of faster aspart were *30% greater in
elderly than in younger adults, there were no age
group differences in the total or maximum glucose-
lowering effect of faster aspart.
The ultra-fast pharmacokinetic and
pharmacodynamic properties of faster aspart
observed in younger adults are preserved in the
elderly, suggesting that faster aspart also has the
potential to improve postprandial glucose control
over current rapid-acting insulin analogues in elderly
patients with diabetes.
Electronic supplementary material The online version of this
article (doi:10.1007/s40266-016-0418-6) contains supplementary
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1 Introduction
Due to a continuously growing elderly population, the
number of elderly patients with diabetes who are being
treated with insulin is also increasing [1]. One implication
of this is that it has become even more important to char-
acterise the pharmacokinetic and pharmacodynamic prop-
erties of any new insulin product specifically in the elderly
population.
Faster-acting insulin aspart (faster aspart) is insulin
aspart in a new formulation with two added excipients
(L-arginine and niacinamide), which are both listed in the US
Food and Drug Administration (FDA) inactive ingredient
database as products approved for injection [2]. L-arginine
acts as a stabilising agent, while niacinamide results in
faster initial absorption after subcutaneous administration.
The aim of this formulation is to improve postprandial
glucose control over current rapid-acting insulins. Clinical
pharmacology studies have shown that faster aspart has an
onset of appearance that is twice as fast and a twofold
higher early insulin exposure than insulin aspart, which
leads to more than 50% greater early glucose-lowering
effect [3–5]. In phase III trials conducted in subjects with
type 1 (T1DM) and type 2 (T2DM) diabetes mellitus,
postprandial glucose increments in standardised meal-tests
were reduced with faster aspart versus insulin aspart [6, 7].
As the majority of subjects in these previous studies with
faster aspart were below 65 years of age, there is a need for
specific knowledge about the pharmacological properties
of faster aspart in the elderly population.
The objectives of the current study were to investigate
the overall pharmacokinetic and pharmacodynamic char-
acteristics of faster aspart in elderly subjects compared
with those in younger adults, and to compare the early
pharmacokinetic and pharmacodynamic properties between
faster aspart and insulin aspart in elderly subjects using the
same comparison in younger adults as a reference. The
study was conducted in subjects with T1DM in order to be
able to assess the glucose-lowering effect of the investi-
gational insulins in a glucose clamp setting, without
interference from endogenous insulin secretion.
2 Methods
2.1 Trial Design
This was a randomised, single-centre (Profil, Neuss, Ger-
many), double-blind, two-period, crossover trial in elderly
and younger adults with T1DM. The trial protocol was
reviewed and approved by the local health authority
(Bundesinstitut fu¨r Arzneimittel und Medizinprodukte) and
by an independent ethics committee (A¨rztekammer Nord-
rhein). The trial was performed in accordance with the
Declaration of Helsinki, the International Conference on
Harmonisation Good Clinical Practice and relevant regu-
latory guidance on clinical trials in the elderly [8–10].
Written informed consent was obtained before initiation of
any trial-related activities. The trial was registered at
ClinicalTrials.gov (trial identifier: NCT02003677).
2.2 Participants
Eligible subjects were elderly (C65 years) or younger adult
(18–35 years) men and women diagnosed with T1DM
C12 months before being included in the trial who were
treated with multiple daily insulin injections or continuous
subcutaneous insulin infusion for C12 months (total daily
insulin dose\1.2 (I)U/kg/day and total daily bolus insulin
dose \0.7 (I)U/kg/day), with glycosylated haemoglobin
(HbA1c) B9.5% (80 mmol/mol), body mass index (BMI)
18.5–28.0 kg/m2 and fasting C-peptide B0.3 nmol/L.
Subjects were excluded if they had clinically significant
concomitant diseases or clinically significant abnormal
values in clinical laboratory screening tests, were smokers
or were treated with any drugs that might interfere with
glucose metabolism.
2.3 Procedures
The trial consisted of a screening visit (3–21 days before
the first dosing visit), two dosing visits separated by
3–12 days of washout and a follow-up visit (7–21 days
after the second dosing visit). At the dosing visits, sub-
jects received single 0.2 U/kg dosing of faster aspart
(100 U/mL; Novo Nordisk, Bagsværd, Denmark) or
insulin aspart (NovoRapid; 100 U/mL; Novo Nordisk)
in a randomised sequence. Both trial products were pro-
vided in a blinded PDS290 pen-injector prefilled pen
(Novo Nordisk) and were administered by subcutaneous
injection into a lifted skin fold of the lower abdominal
wall above the inguinal area.
At each dosing visit, subjects attended the clinic in the
morning after an overnight fast. They were advised to
avoid any physical exercise during the last 2 days before
each dosing visit and to come to the clinic by car, taxi or
public transport. Subjects received a single dose of trial
product in a euglycaemic glucose clamp setting
(ClampArt; Profil, Neuss, Germany) as previously
described [4]. The blood glucose (BG) clamp target level
was 5.5 mmol/L (100 mg/dL) and the clamp lasted up to
12 h after dosing. The quality of the conducted clamps [11]
for each treatment and age group is presented in the
Electronic Supplementary Material (Online Resource
Table S1).
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Blood samples for pharmacokinetic assessment were
drawn within 2 min before dosing, then every 2 min from
dosing until 20 min after dosing, every 5 min from 20 to
80 min, every 10 min from 80 min to 2 h, every 15 min
from 2 to 3 h, and then at 3.5, 4, 5, 6, 7, 8, 10 and 12 h after
dosing.
2.4 Assessments
Free serum insulin aspart concentrations (polyethylene
glycol-precipitated) were measured by a validated insulin
aspart-specific enzyme-linked immunosorbent assay. The
glucose infusion rate (GIR) needed to keep the BG con-
centration at the clamp target level was recorded auto-
matically every minute during the glucose clamp. Safety
assessments included adverse events, local tolerability at
the injection site, hypoglycaemic episodes, laboratory
safety parameters, physical examination, vital signs and
electrocardiogram. Hypoglycaemic episodes were defined
as ‘confirmed’ when they were either ‘severe’ according to
American Diabetes Association criteria, i.e. requiring third-
party assistance [12], or verified by a plasma glucose level
of\3.1 mmol/L (56 mg/dL).
2.5 Endpoints
Endpoints evaluating onset of exposure and onset of glu-
cose-lowering effect included the pharmacokinetic end-
points, onset of appearance (time from trial product
administration until the first time serum insulin aspart
concentration was greater than or equal to the lower limit
of quantification [LLOQ; 10 pmol/L]), time to early 50%
of maximum insulin aspart concentration (tEarly 50% Cmax)
and time to maximum insulin aspart concentration (tmax),
and the pharmacodynamic endpoints, onset of action (time
from trial product administration until the BG concentra-
tion had decreased by at least 0.3 mmol/L [5 mg/dL] from
baseline, where baseline was defined as the mean BG
concentration from -5 to -1 min), time to early 50% of
maximum GIR (tEarly 50% GIRmax) and time to maximum
GIR (tGIRmax). Early exposure and early glucose-lowering
effect were evaluated by deriving the early partial area
under the concentration–time curve (AUC) values for
serum insulin aspart (AUC for insulin aspart from time zero
to 15 min [AUCIAsp,0-15 min], 30 min [AUCIAsp,0-30 min], 1 h
[AUCIAsp,0-1 h], 1.5 h [AUCIAsp,0-1.5 h], and 2 h
[AUCIAsp,0-2 h]) to assess pharmacokinetics and the AUCs
for GIR (AUC for GIR from time zero to 30 min
[AUCGIR,0-30 min], 1 h [AUCGIR,0-1 h], 1.5 h [AUCGIR,0-1.5 h],
and 2 h [AUCGIR,0-2 h]) to assess pharmacodynamics.
Overall exposure and glucose-lowering effect were evalu-
ated by deriving the pharmacokinetic endpoints,
total insulin aspart exposure (AUCIAsp,0-t) and maximum
insulin aspart concentration (Cmax), and the pharmacody-
namic endpoints, total glucose-lowering effect (AUCGIR,0-t;
primary endpoint) and maximum GIR (GIRmax).
In order to calculate onset of appearance and
AUCIAsp,0-15 min, the insulin aspart concentration was
imputed during the period from dosing of trial product
until the time of the first insulin aspart concentration above
LLOQ using compartmental modelling. This approach was
also used for the initial part of the AUC in calculating all
other AUCIAsp endpoints for consistency. AUCIAsp,0-t was
derived by calculating the AUC until the time of last
quantifiable insulin aspart concentration and then extrapo-
lating until 12 h (the last pharmacokinetic sampling time-
point) based on the terminal slope. AUCGIR,0-t was
calculated until time of last GIR observation[0. In order to
ensure robust calculation of tEarly 50% GIRmax, GIRmax and
tGIRmax, these endpoints were derived from LOESS
smoothed GIR profiles (using a smoothing factor of 0.1).
All other endpoints were derived from the raw profiles.
2.6 Statistical Analyses
No formal sample size calculation was performed. Before
initiation of the trial, the number of subjects required to
complete the trial was set to 40 (20 in each age group).
With this sample size, assuming a total variance of
log(AUCGIR,0-t) of 0.17 [3], the 95% confidence interval
(CI) for the ratio of elderly/younger adults with respect to
AUCGIR,0-t would be expected to range from 0.77 to 1.30
times the estimated age group ratio. This was considered a
sufficient precision for the current study. To account for
potential dropouts, it was pre-planned to randomise 44
subjects (22 subjects per age group).
All statistical analyses were performed at a 5% signifi-
cance level using all randomised subjects who received at
least one dose of trial product. SAS version 9.3 (SAS
Institute, Cary, NC, USA) was used for all analyses.
Pharmacokinetic and pharmacodynamic endpoints were
log-transformed (except for onset of appearance,
tEarly 50% Cmax, tmax, onset of action, tEarly 50% GIRmax,
tGIRmax and AUCGIR,0-30 min) and analysed in a linear
mixed model with age group, treatment, interaction
between age group and treatment, and period as fixed
effects and subject as a random effect. The variance of the
random subject effect and the residual variance depended
on the age group. The pharmacokinetic and pharmacody-
namic properties were compared between faster aspart and
insulin aspart for elderly and younger adults using treat-
ment ratios and 95% CIs derived by back-transforming the
model-based treatment differences and corresponding CIs.
Treatment ratios and 95% CIs for endpoints analysed
without log-transformation were calculated by Fieller’s
method [13]. To compare overall insulin exposure and
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overall glucose-lowering effect between elderly and
younger adults for both faster aspart and insulin aspart, age
group ratios and 95% CIs were calculated for AUCIAsp,0-t,
Cmax, AUCGIR,0-t (statistical analysis of primary endpoint)
and GIRmax from the same model as described above. For
all analyses, a p value for test of no interaction between age
group and treatment was derived.
Safety endpoints were summarised by descriptive
statistics for subjects receiving at least one dose of trial
product.
3 Results
3.1 Subject Disposition and Baseline Characteristics
A total of 85 subjects were screened and 67 subjects (30
elderly and 37 younger adults) were randomised and
treated with trial product (Online Resource Fig. S1). Two
subjects (one elderly and one younger adult) withdrew
consent after the first dosing visit (insulin aspart and faster
aspart, respectively). Thus, 29 elderly subjects and 36
younger adults completed the trial. All 67 randomised
subjects were included in the pharmacokinetic and safety
analyses. A total of 23 randomised subjects (8 elderly and
15 younger adults) were excluded from the pharmacody-
namic analysis based on a blinded review conducted after
completion of the first 44 subjects. During this blinded
review, it was discovered that the Biostator algorithm
[14], used at that time by ClampArt, to determine the
GIR based on BG concentrations did not consistently
react fast enough to the rapid changes in metabolic
activity induced by the study insulins. This led to high
oscillations in BG and GIR, particularly shortly after
dosing, in some clamp experiments depending on the
exact glucodynamics. The technical issue affected at least
one of the two glucose clamps in each of the 23 subjects,
implying that clamp quality was insufficient for the valid
calculation and interpretation of pharmacodynamic end-
points, especially in the early post-dosing period. The
algorithm was therefore optimised to react faster to
changes in BG and to reduce the high oscillations in BG
and GIR observed with the Biostator algorithm. Both the
Biostator algorithm and the optimised algorithm are pro-
portional–integral–derivative (PID) controllers with
comparable design, but with different aggressiveness. In
order to achieve the planned number of completers for
pharmacodynamic evaluation, 23 additional subjects were
subsequently enrolled and assigned to the same treatment
sequence as the subject being replaced. Thus, 44 subjects
(22 in each age group) were included in the pharmaco-
dynamic analysis. As the pharmacokinetic data were not
affected by the technical clamp issues, the
pharmacokinetic data obtained in the replaced subjects
were included in the analysis (Online Resource Fig. S1).
Subject characteristics were comparable between age
groups, except for the pre-defined difference in age
between the two groups and the consequently longer
duration of diabetes in the elderly group (Table 1).
3.2 Treatment Differences in Onset of Exposure
and Glucose-Lowering Effect
In elderly subjects, both the mean serum insulin aspart
concentration–time profile (Fig. 1) and the glucose-lowering
effect–time profile (Fig. 2) were left-shifted for faster
aspart compared with insulin aspart. Similar left-shifts of
the pharmacokinetic and pharmacodynamic profiles were
observed in younger adults (Online Resource Figs. S2 and
S3).
Onset of appearance of faster aspart in the elderly sub-
jects occurred twice as fast (*3 min earlier; p\ 0.001),
and tEarly 50% Cmax was shorter by *10 min (p\ 0.001),
as compared with insulin aspart (Table 2). In the elderly
subjects, tmax occurred 7 min earlier for faster aspart than
for insulin aspart; however, the difference was not statis-
tically significant (Table 2). Similar results were obtained
with respect to onset of exposure in younger adults (Online
Resource Table S2). Accordingly, the effect of treatment
on onset of exposure did not differ statistically significantly
between elderly and younger adults. p values for treatment
by age group interaction were 0.904, 0.304 and 0.760 for
onset of appearance, tEarly 50% Cmax and tmax, respectively.
Onset of action and tEarly 50% GIRmax occurred *10 min
faster (p\ 0.001) and *6 min earlier (p = 0.003),





Age (years) 68.1 (2.7) 27.4 (4.1)
Sex
Female [n (%)] 11 (36.7) 14 (37.8)
Male [n (%)] 19 (63.3) 23 (62.2)
Race
White [n (%)] 30 (100.0) 36 (97.3)
Othera [n (%)] 0 (0.0) 1 (2.7)
Body weight (kg) 74.5 (12.1) 76.5 (10.6)
BMI (kg/m2) 24.8 (2.4) 24.7 (2.1)
Duration of diabetes (years) 37.5 (12.0) 14.0 (6.3)
HbA1c (%) 7.2 (0.8) 7.5 (0.8)
HbA1c (mmol/mol) 55 (9) 58 (9)
Data are mean (standard deviation) unless otherwise stated
BMI body mass index, HbA1c glycosylated haemoglobin
a Mixed race
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respectively, with faster aspart compared with insulin
aspart in the elderly subjects, while tGIRmax did not differ
statistically significantly between treatments (Table 2). A
similarly accelerated onset of glucose-lowering effect was
obtained in the group of younger adults (Online Resource
Table S2). No statistically significant differences between
elderly and younger adults were observed with respect to
treatment effect for onset of glucose-lowering effect.
p values for the treatment by age group interaction were
0.707, 0.121 and 0.948 for onset of action, tEarly 50% GIRmax
and tGIRmax, respectively.
3.3 Treatment Differences in Early Exposure
and Glucose-Lowering Effect
In the elderly subjects, early insulin exposure up to 2 h
after dosing was statistically significantly greater for faster
aspart than for insulin aspart (Fig. 3a). Insulin exposure
was *3-fold greater during the first 15 min after dosing
(AUCIAsp,0-15 min; p\ 0.001) and *2-fold greater within
the first 30 min after dosing (AUCIAsp,0-30 min; p\ 0.001)
for faster aspart than for insulin aspart. Similar results were
obtained in younger adults, although the treatment differ-
ence for AUCIAsp,0-1.5 h and AUCIAsp,0-2 h did not reach
statistical significance in this age group (Online Resource
Fig. S4). The treatment effect on early exposure was not
statistically significantly different between age groups.
p values for treatment by age group interaction were 0.283,
0.449, 0.583, 0.622 and 0.663 for AUCIAsp,0-15 min,
AUCIAsp,0-30 min, AUCIAsp,0-1 h, AUCIAsp,0-1.5 h and
AUCIAsp,0-2 h, respectively.
Early glucose-lowering effect was statistically signifi-
cantly greater for faster aspart than for insulin aspart in the
elderly subjects up to 2 h after dosing (Fig. 3b). An *2-
fold greater glucose-lowering effect was observed with
faster aspart than with insulin aspart within the first 30 min
after dosing (AUCGIR,0-30 min; p = 0.001). Similar treat-
ment differences were observed in the group of younger
adults, although the treatment difference for AUCGIR,0-2 h
did not reach statistical significance in this age group



































































Fig. 1 Mean serum insulin aspart concentration–time profiles for 5 h
(a) and 2 h (b) after administration of faster aspart and insulin aspart
(0.2 U/kg) in elderly subjects with type 1 diabetes mellitus
























































Fig. 2 Mean glucose-lowering effect–time profiles for 5 h (a) and
2 h (b) after administration of faster aspart and insulin aspart (0.2 U/
kg) in elderly subjects with type 1 diabetes mellitus
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Table 2 Onset of exposure and glucose-lowering effect after administration of faster aspart versus insulin aspart (0.2 U/kg) in elderly subjects
with type 1 diabetes mellitus
Faster asparta Insulin asparta Treatment ratiob [95% CI] Treatment differencec [95% CI] p valued
Onset of exposure
Onset of appearance (min) 2.4 5.2 0.45 [0.30–0.60] –2.9 [–3.8 to -1.9] \0.001
tEarly 50% Cmax (min) 18.2 28.0 0.65 [0.56–0.74] –9.8 [–12.7 to -7.0] \0.001
tmax (min) 57.2 64.2 0.89 [0.75–1.06] –7.0 [–17.6 to 3.6] 0.187
Onset of glucose-lowering effect
Onset of action (min) 19.0 29.1 0.65 [0.51–0.81] –10.2 [–15.3 to -5.1] \0.001
tEarly 50% GIRmax (min) 32.1 37.7 0.85 [0.77–0.94] –5.6 [–9.0 to -2.2] 0.003
tGIRmax (min) 136.2 145.8 0.93 [0.79–1.10] –9.6 [–33.7 to 14.5] 0.415
CI confidence interval, tEarly 50% Cmax time to 50% of maximum insulin aspart concentration in the early part of the pharmacokinetic profile,
tEarly 50% GIRmax time to 50% of maximum glucose infusion rate in the early part of the glucose infusion rate profile, tGIRmax time to maximum
glucose infusion rate, tmax time to maximum insulin aspart concentration
a Data are least square means
b Faster aspart/insulin aspart (calculated using Fieller’s method)
c Faster aspart – insulin aspart














































































Fig. 3 Early exposure (a) and glucose-lowering effect (b) after
administration of faster aspart versus insulin aspart (0.2 U/kg) in
elderly subjects with type 1 diabetes mellitus. AUC area under the
curve, CI confidence interval, GIR glucose infusion rate, IAsp insulin
aspart, LS Mean least square mean, P-value treatment comparison of
faster aspart versus insulin aspart
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(Online Resource Fig. S4). There was no statistically sig-
nificant impact of age group on the treatment differences in
early glucose-lowering effect. p values for treatment by
age group interaction were 0.914, 0.605, 0.869 and 0.959
for AUCGIR,0-30 min, AUCGIR,0-1 h, AUCGIR,0-1.5 h and
AUCGIR,0-2 h, respectively.
3.4 Treatment Differences in Overall Exposure
and Glucose-Lowering Effect
AUCIAsp,0-t, Cmax, AUCGIR,0-t and GIRmax were all com-
parable for faster aspart and insulin aspart, irrespective of
age group (Table 3 and Online Resource Table S3).
3.5 Age Group Differences in Overall Exposure
and Glucose-Lowering Effect
AUCIAsp,0-t and Cmax for faster aspart were greater in
elderly than in younger adults (estimated ratio of elderly/
younger adults [95% CI] 1.30 [1.07–1.57], p = 0.008, and
1.28 [1.02–1.61], p = 0.031) (Table 4). For insulin aspart,
the point estimates for the age group ratios were
comparable with those for faster aspart, although no sta-
tistically significant difference was seen for Cmax. The
effect of age on overall exposure did not differ statistically
significantly between faster aspart and insulin aspart.
p values for treatment by age group interaction were 0.867
and 0.431 for AUCIAsp,0-t and Cmax, respectively.
There were no statistically significant differences in
AUCGIR,0-t and GIRmax between elderly and younger adults
for faster aspart or for insulin aspart (estimated ratio of
elderly/younger adults [95% CI] 0.93 [0.73–1.17],
p = 0.517, and 0.85 [0.66–1.10], p = 0.209) (Table 4).
p values for treatment by age group interaction were 0.403
and 0.430 for AUCGIR,0-t and GIRmax, respectively.
Least square means for AUCIAsp,0-t, Cmax, AUCGIR,0-t
and GIRmax for both faster aspart and insulin aspart are
presented for elderly subjects in Table 3 and for younger
adults in Online Resource Table S3.
3.6 Safety
Faster aspart and insulin aspart were well-tolerated in both
elderly and younger adults, and no safety issues were
Table 3 Overall exposure and
glucose-lowering effect after
administration of faster aspart
versus insulin aspart (0.2 U/kg)
in elderly subjects with type 1
diabetes mellitus
Faster asparta Insulin asparta Treatment ratiob [95% CI] p valuec
Overall exposure
AUCIAsp,0-t (pmolh/L) 929.1 880.9 1.05 [0.98–1.14] 0.152
Cmax (pmol/L) 406.9 367.6 1.11 [1.00–1.23] 0.060
Overall glucose-lowering effect
AUCGIR,0-t (mg/kg) 1136.7 1012.5 1.12 [0.94–1.35] 0.198
GIRmax (mg/kg/min) 5.6 4.9 1.13 [0.96–1.33] 0.126
AUCGIR,0-t total glucose-lowering effect, AUCIAsp,0-t total insulin aspart exposure, CI confidence interval,
Cmax maximum insulin aspart concentration, GIRmax maximum glucose infusion rate
a Data are least square means
b Faster aspart/insulin aspart
c For treatment comparison of faster aspart versus insulin aspart
Table 4 Overall exposure and glucose-lowering effect after administration of faster aspart and insulin aspart (0.2 U/kg) in elderly versus
younger adults with type 1 diabetes mellitus
Faster aspart Insulin aspart
Ratio of elderly/younger
adults [95% CI]




AUCIAsp,0-t (pmolmin/L) 1.30 [1.07–1.57] 0.008 1.32 [1.09–1.59] 0.005
Cmax (pmol/L) 1.28 [1.02–1.61] 0.031 1.20 [0.96–1.50] 0.111
Overall glucose-lowering effect
AUCGIR,0-t (mg/kg) 0.93 [0.73–1.17]
b 0.517 0.85 [0.67–1.07] 0.160
GIRmax (mg/kg/min) 0.85 [0.66–1.10] 0.209 0.78 [0.60–1.01] 0.055
AUCGIR,0-t total glucose-lowering effect, AUCIAsp,0-t total insulin aspart exposure, CI confidence interval, Cmax maximum insulin aspart con-
centration, GIRmax maximum glucose infusion rate
a For age group comparison of elderly versus younger adults
b Statistical analysis of primary endpoint
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identified during the trial. There were no serious adverse
events and all adverse events were either moderate (six
events for faster aspart and eight events for insulin aspart)
or mild (nine for faster aspart and two for insulin aspart) in
intensity. No confirmed hypoglycaemic episodes and no
injection-site reactions occurred during the trial.
4 Discussion
The main findings of the present study were the faster onset
and greater early exposure and glucose-lowering effect
observed with faster aspart versus insulin aspart in elderly
subjects. The left shift of the pharmacokinetic and phar-
macodynamic profiles of faster aspart versus insulin aspart
in the elderly mirrors that seen in younger adults in the
current study as well as in previous studies [3–5], indi-
cating that the ultra-fast pharmacological properties of
faster aspart are preserved in elderly patients with diabetes.
The faster onset and greater early glucose-lowering
effect of faster aspart than with insulin aspart indicate that
faster aspart better mimics the insulin action seen in the
healthy state in response to a meal. Thus, faster aspart may
provide better mealtime coverage than current rapid-acting
insulins. Indeed, in subjects with T1DM, superiority of
faster aspart over insulin aspart in 2-h postprandial glucose
excursion and a statistically significant difference in favour
of faster aspart in 1-h postprandial glucose excursion were
demonstrated in a meal-test [6]. Likewise, in subjects with
T2DM, the 1-h postprandial glucose excursion was statis-
tically significantly reduced for faster aspart versus insulin
aspart, while the treatment difference in 2-h postprandial
glucose excursion in favour of faster aspart did not reach
statistical significance [7]. These two latter trials were
conducted mainly in younger adults [6, 7]. On the basis of
the results of the current study we would hypothesise that
similar improvements in postprandial glucose excursions
would be achieved in elderly patients with diabetes.
However, the potential for faster aspart to improve post-
prandial glucose control in elderly patients with diabetes
still remains to be confirmed in further investigations.
The faster pharmacokinetic and pharmacodynamic
properties of faster aspart may provide the option of post-
meal administration, when necessary, thereby allowing the
insulin dose to be more accurately adjusted to the actual
food intake. This could be particularly useful in those
elderly patients with cognitive impairment and/or irregular
eating patterns. Potential benefits include improved control
of postprandial glucose and, not least, a reduced risk of
hypoglycaemia, which is considered a particularly serious
problem and a barrier to optimal glycaemic control in
elderly patients with diabetes [15, 16]. In a standardised
meal-test in elderly subjects with T2DM, insulin aspart
administered at meal ingestion and regular human insulin
administered 30 min before meal ingestion resulted in
similar insulin and postprandial glucose profiles [17]. Post-
meal insulin lispro provided greater control of mean daily
BG and a reduced incidence of hypoglycaemia and
hyperglycaemia compared with regular human insulin
administered 30 min before each meal in elderly subjects
with T2DM living in nursing homes [18]. Thus, it appears
that current rapid-acting insulins allow for post-meal
dosing, while still providing at least as good postprandial
glucose control as regular human insulin administered pre-
meal. In a similar manner, faster aspart administered
20 min post-meal has been compared with insulin aspart
administered at mealtime in adult subjects with T1DM [6].
The 2-h postprandial glucose increment was not statisti-
cally significantly different between post-meal faster aspart
and mealtime insulin aspart, while the 1-h postprandial
glucose increment was statistically significantly in favour
of mealtime insulin aspart. The HbA1c reduction seen
during the 26-week treatment period was non-inferior, and
overall rates of severe and confirmed hypoglycaemia were
comparable, for post-meal faster aspart versus mealtime
insulin aspart [6]. Clinical evidence is needed to confirm
the option of post-meal dosing of faster aspart in elderly
patients with diabetes and the optimal time window for
such administration.
We found a higher total exposure and Cmax of faster
aspart in elderly than in younger adults. The same was seen
for insulin aspart, although it was only statistically signi-
ficant for total exposure. A similar trend has been observed
in previous studies for the insulin degludec/insulin aspart
combination, insulin degludec alone and for insulin detemir
[19–21], and would be in accordance with a reduced insulin
clearance with increasing age [22]. Importantly, we found
comparable AUCGIR,0-t and GIRmax in elderly and younger
adults, as previously shown [19]. The similar glucose-
lowering effect in elderly and younger adults despite higher
exposure in the elderly is in line with the well-known
decrease in insulin sensitivity with aging [23, 24]. In this
context, it is also important to emphasise that the insulin
dose should always be adjusted on an individual basis,
depending on each patient’s needs. It follows that faster
aspart should be considered safe also in elderly diabetes
patients in terms of possible hypoglycaemia, although
clinical data are needed to confirm this.
The clamp quality in the current study was high both in
terms of precision and control deviation (Online Resource
Table S1). Thus, the technical clamp issues experienced
during the initial part of the study seem to have had no
adverse impact on the quality of the results, as would also
be expected since the affected data were excluded during a
blinded review (see Sect. 3.1). In fact, the control deviation
(i.e. the mean difference between the measured and the
36 T. Heise et al.
target BG concentration) was lower than in a previous series
of experiments using the Biostator algorithm [11]. Thus,
optimising the algorithm as done during the present study
may have contributed to reducing the control deviation.
Several review articles have emphasised the generally
limited number of clinical trials investigating diabetes
interventions in the elderly [25–27]. Accordingly, to our
knowledge, glucose clamp studies comparing the pharma-
cokinetic and pharmacodynamic properties of an insulin
between elderly and younger adults and/or between two
insulins in elderly subjects have only been conducted for a
few insulin products [19, 20, 28]. Therefore, a strength of
the current study was the use of the euglycaemic glucose
clamp technique to assess the pharmacodynamic proper-
ties. It is, however, also important to emphasise that an
inherent limitation of the glucose clamp method is the
experimental and standardised setting, which imposes
some challenges in directly translating to clinical practice.
Another limitation of the present study was the relatively
few subjects per age group. Still, the number of subjects
was higher than in similar previous studies in elderly
subjects [19, 20], and was sufficient to demonstrate sta-
tistically significant differences in pharmacokinetic and
pharmacodynamic properties between faster aspart and
insulin aspart in both age groups.
5 Conclusion
The present study demonstrated that faster aspart has a
faster onset and a greater early exposure and glucose-
lowering effect than insulin aspart in elderly subjects with
T1DM. The results observed in the elderly subjects are in
line with those seen in the younger adults, suggesting that
faster aspart also has the potential to improve postprandial
glucose control compared with current rapid-acting insu-
lins in elderly patients with diabetes.
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